Evidence map›Paper›PMID 34310084›Full record

ArticleAnnals of clinical and translational neurology2021

Distinct progression patterns across Parkinson disease clinical subtypes.

Peter S Myers, Joshua J Jackson, Amber K Clover, Christina N Lessov-Schlaggar, Erin R Foster, Baijayanta Maiti, Joel S Perlmutter, Meghan C Campbell

Registry-linked trialAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07024875 (Precision Neuroimaging of Parkinson's Disease), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07024875 recruitingnot on this mapstarted 2025, after this paper: background citation

Precision Neuroimaging of Parkinson's Disease

Typeobservational_patient_registrySponsorWashington University School of MedicineRan2025 to 2031Enrolled120ConditionsParkinsons Disease (PD)
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peter S MyersDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0003-2582-691X
Joshua J JacksonDepartment of Psychological and Brain Sciences, Washington University in St. Louis, St. Louis, Missouri, USA.
Amber K CloverDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Christina N Lessov-SchlaggarDepartment of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
Erin R FosterDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Baijayanta MaitiDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Joel S PerlmutterDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Meghan C CampbellDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0003-3030-9669

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Washington University Institute of Clinical and Translational Sciences (UL1)UL1RR024992 · NCRR · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2007 to 2011
$45.4M
INVESTIGATIONS OF DEMENTIA IN PARKINSON DISEASER01NS075321 · NINDS · WASHINGTON UNIVERSITY · PI CAMPBELL, MEGHAN C, PERLMUTTER, JOEL SYNES · 2011 to 2021
$8.2M
proj 3 - NINDS INSTIUTIONAL CENTER CORE GRANTS TO SUPPORT NEUROSCIENCE RESEARP30NS048056 · NINDS · WASHINGTON UNIVERSITY · PI MINTUN, MARK A. · 2004 to 2014
$7.4M
MECHANISMS OF DEEP BRAIN STIMULATIONR01NS041509 · NINDS · WASHINGTON UNIVERSITY · PI PERLMUTTER, JOEL SYNES · 2001 to 2015
$6.8M
VALIDATION OF NEUROIMAGING BIOMARKERS FOR NIGROSTRIATAL NEURONSR01NS058714 · NINDS · WASHINGTON UNIVERSITY · PI PERLMUTTER, JOEL SYNES · 2008 to 2016
$4.4M
Parkinson Disease Clinical Subtypes: Validation, Clinical Utility, and Biological CorrelatesR01NS097437 · NINDS · WASHINGTON UNIVERSITY · PI MEGHAN C CAMPBELL · 2017 to 2026
$4.1M
Investigations of Dementia in Parkinson DiseaseRF1NS075321 · NINDS · WASHINGTON UNIVERSITY · PI CAMPBELL, MEGHAN C, PERLMUTTER, JOEL SYNES · 2023 to 2023
$2.3M
Neurodegenerative consequences of PanK2 mutationsK08NS048924 · NINDS · WASHINGTON UNIVERSITY · PI KOTZBAUER, PAUL T · 2004 to 2008
$878k
NCATS NIH HHS UL1 TR002345NCRR NIH HHS UL1 RR024992NINDS NIH HHS K08 NS048924NINDS NIH HHS P30 NS048056NINDS NIH HHS R01 NS041509NINDS NIH HHS R01 NS058714NINDS NIH HHS R01 NS075321NINDS NIH HHS R01 NS097437NINDS NIH HHS RF1 NS075321
6 · The paper itself

Abstract

objectiveTo examine specific symptom progression patterns and possible disease staging in Parkinson disease clinical subtypes.

methodsWe recently identified Parkinson disease clinical subtypes based on comprehensive behavioral evaluations, "Motor Only," "Psychiatric & Motor," and "Cognitive & Motor," which differed in dementia and mortality rates. Parkinson disease participants ("Motor Only": n = 61, "Psychiatric & Motor": n = 17, "Cognitive & Motor": n = 70) and controls (n = 55) completed longitudinal, comprehensive motor, cognitive, and psychiatric evaluations (average follow-up = 4.6 years). Hierarchical linear modeling examined group differences in symptom progression. A three-way interaction among time, group, and symptom duration (or baseline age, separately) was incorporated to examine disease stages.

resultsAll three subtypes increased in motor dysfunction compared to controls. The "Motor Only" subtype did not show significant cognitive or psychiatric changes compared to the other two subtypes. The "Cognitive & Motor" subtype's cognitive dysfunction at baseline further declined compared to the other two subtypes, while also increasing in psychiatric symptoms. The "Psychiatric & Motor" subtype's elevated psychiatric symptoms at baseline remained steady or improved over time, with mild, steady decline in cognition. The pattern of behavioral changes and analyses for disease staging yielded no evidence for sequential disease stages.

interpretationParkinson disease clinical subtypes progress in clear, temporally distinct patterns from one another, particularly in cognitive and psychiatric features. This highlights the importance of comprehensive clinical examinations as the order of symptom presentation impacts clinical prognosis.

Indexed as

Disease ProgressionAgedCognitive DysfunctionDyskinesiasFemaleHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsParkinson Disease

Identifiers

PMID34310084
PMCPMC8351397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.